BMP2和BMP7基因共转染BMSC/PRP凝胶组织工程材料的构建及体内外实验研究
|
摘要
研究目的本课题拟制作并证明BMP2、BMP7基因共转染骨髓间充质干细胞/自体PRP凝胶复合组织工程骨在体内有良好的成骨能力和生物安全性，可以达到植骨融合材料的要求。建立可替代自体骨和其他骨移植替代物的组织工程骨。
研究方法将两月龄的新西兰兔36只随机分为4组，每组9只。第一组为单纯植入PRP凝胶组；第二组为植入转染BMP2的BMSCs/PRP凝胶组织工程骨组；第三组为植入转染BMP7的BMSCs/PRP组织工程骨组；第四组为植入共转染BMP2，7的BMSCs/PRP凝胶组织工程骨组。
获取、分离、培养、扩增兔骨髓间充质干细胞BMSCs并检测，第三代细胞保存并选取为待转染细胞。以pAd/CMV/V5-Dest为载体构建BMP2和BMP7腺病毒，将两种基因按照分组分别转染第三代兔BMSCs。
从每只兔子的耳中央静脉抽取5ml全血，采用Lendersberg法制备得到PRP，并于-20℃保存。
将BMP2和BMP7共转染的BMSCs和PRP混合后激活，制备得到BMP2、BMP7基因共转染骨髓间充质干细胞/自体富血小板凝胶支架组织工程骨，部分培养7天后对该组织工程骨进行电镜扫描观察其组织学和形态学。
制备新西兰兔胫骨缺损模型，在胫骨平台下方约2cm处用钻头磨出大小约为3mm×5mm×7mm大小的单皮质骨缺损槽，按照分组分别植入材料，丝线间断缝合伤口后将动物分笼饲养。16周处死动物，观察组织工程骨的表面变化、骨痴形成、骨缺损修复情况及周围组织反应。进行X线和CT检查，观察各组骨愈合情况，行组织学染色观察及电镜观察等。
研究结果BMP2、BMP7基因共转染骨髓间充质干细胞/自体富血小板凝胶支架组织工程骨在体外能良好表达相关基因和蛋白，植入兔体内后无免疫源性，具有良好的成骨作用。其在体内能稳定的表达BMP2与BMP7，较未转染BMP2与BMP7组有更好的骨诱导性能，且其较单基因转染组有更好的成骨活性，可成为替代自体骨和其他骨移植替代物的组织工程材料。
研究结论1、以全骨髓贴壁法可以分离得到具备多向分化潜能的兔BMSCs；2、以pAd/CMV/V5-Dest为载体构建的BMP2腺病毒和BMP7腺病毒能够共转染兔BMSCs，并共同表达BMP2和BMP7；3、以Lendersberg法可以制备得到PRP，和BMP2、BMP7基因共转染BMSCs有很好的组织相容性；4、BMP2、BMP7基因共转染组，较其他组有更好的骨诱导活性和成骨能力，更能促进成骨相关基因和蛋白的表达。
Objective The purpose of this study is to establish an tissue engineering bone withautologous platelet-rich plasma (PRP) gel as scaffold,combined with rabbit bonemarrow mesenchymal stem cells (BMSCs) coexpressed with BMP2and BMP7,andprove it's good osteogenic capacity and bio-security in vivo,which can achieve therequirements of the interbody fusion materials and replace autologous bone and bone graftsubstitutes.
Methods36New Zealand rabbits(two-month-old) were randomly divided into4groups of9. The first group implanted with PRP gel; the second group implanted withautologous platelet-rich plasma (PRP) gel combined with BMP2gene transfectedrabbit bone marrow mesenchymal stem cells (BMSCs); the third group implantedwith autologous platelet-rich plasma (PRP) gel combined with BMP2genetransfected rabbit bone marrow mesenchymal stem cells (BMSCs), the forth groupimplanted with autologous platelet-rich plasma (PRP) gel combined with BMP2,7gene co-transfected rabbit bone marrow mesenchymal stem cells (BMSCs).
To obtain,isolate,culture and amplified rabbit bone marrow mesenchymal stem cells and check,select the third generation of cell to be transfected cells. To establish BMP2and BMP7adenovirus vector wiht pAd/CMV/V5-Dest as the carrier, and transfect the two genes into thethird generation of the rabbit BMSCs.
5ml of whole blood was taken from ear central vein in each rabbit, PRP is prepared using theLendersberg method, and stored at-20℃.
Mix and activate BMP2and BMP7co-transfected BMSCs and PRP, establish the tissueengineering bone with autologous platelet-rich plasma (PRP) gel combined withrabbit bone marrow mesenchymal stem cells (BMSCs) coexpressed with BMP2andBMP7,Part of which culture7days,then to observe the histological and morphological by scanning electron microscopy.
Preparation of New Zealand rabbit lumbar defect model: drilling a single cortical bonedefect about2cm below the tibial plateau，the grind size is approximately3mm x5mmx7mm. Implant materials in the bone defect in accordance with the grouping.
4，8and12week after surgery，we kill3rabbits in each group to observe changes in thetissue-engineered bone surface,callus formation,the repair of bone defect and surrounding tissuereaction. The remaining experimental animals were sacrificed16weeks after surgery,X-ray examination,CT scan, histological staining and electron microscopy are takento observe bone healing in each group.
Results The tissue engineering bone we established with autologous platelet-richplasma (PRP) gel combined with rabbit bone marrow mesenchymal stem cells(BMSCs) coexpressed with BMP2and BMP7,can express genes and proteins related toosteogenesis adequately, without immunogenic,and has a good osteoinductive and osteogenesis invitro.It can express BMP2and BMP7stablely, and it has a better performance of boneinduction compared with untransfected group of BMP2and BMP7and other groups. Thetissue engineering materials we established can become the substitute to autologous bone andother bone graft materials.
Conclusions1、Preparation of BMSCs by bone marrow adherent method was proper.The BMSCs obtained have multilineage differentiation potential.2、BMP2adenovirus and BMP2adenovirus vector in a pAd/CMV/V5-Dest could be transfected in rabbit BMSCs andco-expression of BMP2and BMP7.3、PRP prepared by Lendersberg method have goodhistocompatibility with BMP2, BMP7gene co-transfected BMSCs.4、BMP2, BMP7geneco-transfected group with better expression of osteoblast-related genes and proteins have betterosteoinductive activity and osteogenic capacity, compared with other groups.
研究方法将两月龄的新西兰兔36只随机分为4组，每组9只。第一组为单纯植入PRP凝胶组；第二组为植入转染BMP2的BMSCs/PRP凝胶组织工程骨组；第三组为植入转染BMP7的BMSCs/PRP组织工程骨组；第四组为植入共转染BMP2，7的BMSCs/PRP凝胶组织工程骨组。
获取、分离、培养、扩增兔骨髓间充质干细胞BMSCs并检测，第三代细胞保存并选取为待转染细胞。以pAd/CMV/V5-Dest为载体构建BMP2和BMP7腺病毒，将两种基因按照分组分别转染第三代兔BMSCs。
从每只兔子的耳中央静脉抽取5ml全血，采用Lendersberg法制备得到PRP，并于-20℃保存。
将BMP2和BMP7共转染的BMSCs和PRP混合后激活，制备得到BMP2、BMP7基因共转染骨髓间充质干细胞/自体富血小板凝胶支架组织工程骨，部分培养7天后对该组织工程骨进行电镜扫描观察其组织学和形态学。
制备新西兰兔胫骨缺损模型，在胫骨平台下方约2cm处用钻头磨出大小约为3mm×5mm×7mm大小的单皮质骨缺损槽，按照分组分别植入材料，丝线间断缝合伤口后将动物分笼饲养。16周处死动物，观察组织工程骨的表面变化、骨痴形成、骨缺损修复情况及周围组织反应。进行X线和CT检查，观察各组骨愈合情况，行组织学染色观察及电镜观察等。
研究结果BMP2、BMP7基因共转染骨髓间充质干细胞/自体富血小板凝胶支架组织工程骨在体外能良好表达相关基因和蛋白，植入兔体内后无免疫源性，具有良好的成骨作用。其在体内能稳定的表达BMP2与BMP7，较未转染BMP2与BMP7组有更好的骨诱导性能，且其较单基因转染组有更好的成骨活性，可成为替代自体骨和其他骨移植替代物的组织工程材料。
研究结论1、以全骨髓贴壁法可以分离得到具备多向分化潜能的兔BMSCs；2、以pAd/CMV/V5-Dest为载体构建的BMP2腺病毒和BMP7腺病毒能够共转染兔BMSCs，并共同表达BMP2和BMP7；3、以Lendersberg法可以制备得到PRP，和BMP2、BMP7基因共转染BMSCs有很好的组织相容性；4、BMP2、BMP7基因共转染组，较其他组有更好的骨诱导活性和成骨能力，更能促进成骨相关基因和蛋白的表达。
Objective The purpose of this study is to establish an tissue engineering bone withautologous platelet-rich plasma (PRP) gel as scaffold,combined with rabbit bonemarrow mesenchymal stem cells (BMSCs) coexpressed with BMP2and BMP7,andprove it's good osteogenic capacity and bio-security in vivo,which can achieve therequirements of the interbody fusion materials and replace autologous bone and bone graftsubstitutes.
Methods36New Zealand rabbits(two-month-old) were randomly divided into4groups of9. The first group implanted with PRP gel; the second group implanted withautologous platelet-rich plasma (PRP) gel combined with BMP2gene transfectedrabbit bone marrow mesenchymal stem cells (BMSCs); the third group implantedwith autologous platelet-rich plasma (PRP) gel combined with BMP2genetransfected rabbit bone marrow mesenchymal stem cells (BMSCs), the forth groupimplanted with autologous platelet-rich plasma (PRP) gel combined with BMP2,7gene co-transfected rabbit bone marrow mesenchymal stem cells (BMSCs).
To obtain,isolate,culture and amplified rabbit bone marrow mesenchymal stem cells and check,select the third generation of cell to be transfected cells. To establish BMP2and BMP7adenovirus vector wiht pAd/CMV/V5-Dest as the carrier, and transfect the two genes into thethird generation of the rabbit BMSCs.
5ml of whole blood was taken from ear central vein in each rabbit, PRP is prepared using theLendersberg method, and stored at-20℃.
Mix and activate BMP2and BMP7co-transfected BMSCs and PRP, establish the tissueengineering bone with autologous platelet-rich plasma (PRP) gel combined withrabbit bone marrow mesenchymal stem cells (BMSCs) coexpressed with BMP2andBMP7,Part of which culture7days,then to observe the histological and morphological by scanning electron microscopy.
Preparation of New Zealand rabbit lumbar defect model: drilling a single cortical bonedefect about2cm below the tibial plateau，the grind size is approximately3mm x5mmx7mm. Implant materials in the bone defect in accordance with the grouping.
4，8and12week after surgery，we kill3rabbits in each group to observe changes in thetissue-engineered bone surface,callus formation,the repair of bone defect and surrounding tissuereaction. The remaining experimental animals were sacrificed16weeks after surgery,X-ray examination,CT scan, histological staining and electron microscopy are takento observe bone healing in each group.
Results The tissue engineering bone we established with autologous platelet-richplasma (PRP) gel combined with rabbit bone marrow mesenchymal stem cells(BMSCs) coexpressed with BMP2and BMP7,can express genes and proteins related toosteogenesis adequately, without immunogenic,and has a good osteoinductive and osteogenesis invitro.It can express BMP2and BMP7stablely, and it has a better performance of boneinduction compared with untransfected group of BMP2and BMP7and other groups. Thetissue engineering materials we established can become the substitute to autologous bone andother bone graft materials.
Conclusions1、Preparation of BMSCs by bone marrow adherent method was proper.The BMSCs obtained have multilineage differentiation potential.2、BMP2adenovirus and BMP2adenovirus vector in a pAd/CMV/V5-Dest could be transfected in rabbit BMSCs andco-expression of BMP2and BMP7.3、PRP prepared by Lendersberg method have goodhistocompatibility with BMP2, BMP7gene co-transfected BMSCs.4、BMP2, BMP7geneco-transfected group with better expression of osteoblast-related genes and proteins have betterosteoinductive activity and osteogenic capacity, compared with other groups.
引文
[1]. ContelJR JE,Golden JA,Mcquitty M,et al.Effects of gender,AIDS,and acetylatorstatus on intrapulmonary concentrations of isoniazid[J].Antimicrob AgentsChemother,2002,46(8):2358
[2]. Catelas I, Sese N, Wu BM, et al. Human mesenchymal stem cell proliferation andosteogenic differentiation in fibrin gels in vitro[J].Tissue Eng,2006,12(8):2385.
[3]. Koyama N, Okubo Y, Nakao K, Osawa K, Fujimura K, Bessho K2011Pluripotency of mesenchymal cells derived from synovial fluid in patients withtemporomandibular joint disorder. Biomaterials.33(1):80-90.
[4].柳向东，柴冈，李东，等。成人骨髓间充质干细胞的体外培养和表型鉴定，上海第二医科大学学报，200424:302-306.
[5]. Woo SL, Hildebrand K, Watanabe N, Fenwick JA, Papageorgiou CD, Wang JH1999Tissue engineering of ligament and tendon healing. Clin Orthop Relat Res (367Suppl):S312-23.
[6]. Turgeman G, Pittman DD, Müller R, Kurkalli BG, Zhou S, Pelled G, Peyser A,Zilberman Y, Moutsatsos IK, Gazit D2001Engineered human mesenchymal stemcells: a novel platform for skeletal cell mediated gene therapy. J Gene Med.May-Jun;3(3):240-51.
[7]. Zhou H, Jin Z, Liu J, Yu S, Cui Q, Yi D2008Mesenchymal stem cells might beused to induce tolerance in heart transplantation. Med Hypotheses70(4):785-7.
[8]. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,Grisanti S, Gianni AM2002Human bone marrow stromal cells suppressT-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood.99(10):3838-43.
[9]. Kovacs K，Velich N，HuszarT，et a1．Mistomorphometric and densitometricevaluation of the effects of platelet-rich plasma on the remodeling of beta-tricalciumphosphate in beagle dogs[J]．J Craniofae Surg，2005，16(1)：l50．
[10]. Lucarelli E, Beccheroni A, Donati D, et al. Platelet-derived growth factorsenhance proliferation of human stromal stem cells[J]. Biomaterials2003,24(18):3095.
[11]. FuerstG,Reinhard G,TanglS,et al.Effect of platelet-released growth factors andcollagen type I on osseous regeneration of mandibular defects[J]. J ClinPeriodontol,2004,31(9):784.
[12].羊书勇,毛天球,程晓兵,等。富含血小板血浆凝胶结构用于组织工程载体可能性的扫描电镜观察，中国临床康复,2005,9(26):114-115.
[13].Kim BS, Mooney DJ. Development of biocompatible synthetic extracellularmatrices for tissue engineering [J]. Trends Biotechnol,1998,16(5):224-233.
[14]. Urist MR1965Bone: Formation by autoinduction. Science150:893–899.
[15]. Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, Sibley BS,Wozney JM1988Purification and characterization of other distinct bone-inducingfactors. Proc Natl Acad Sci USA85:9484–9488.
[16]. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, HewickRM, Wang EA1988Novel regulators of bone formation: Molecular clones andactivities. Science242:1528–1534.
[17]. Sampath TK, Coughlin JE, Whetstone RM, Banach D, Corbett C, Ridge RJ,Ozkaynak E, Oppermann H, Rueger DC1990Bovine osteogenic protein is composedof dimers of OP-1and BMP-2A, two members of the transforming growth factor-betasuperfamily. J Biol Chem265:13198–13205.
[18]. Ozkaynak E, Rueger DC, Drier EA, Corbett C, Ridge RJ, Sampath TK,Oppermann H1990OP-1cDNA encodes an osteogenic protein in the TGF-betafamily. EMBO J9:2085–2093.
[19]. Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H, Tsukuda R, Sasaki S,Fujisawa Y1995Potent ectopic boneinducing activity of bone morphogeneticprotein-4/7heterodimer. Biochem Biophys Res Commun210:670–677.
[20]. Hazama M, Aono A, Ueno N, Fujisawa Y1995Efficient expression of aheterodimer of bone morphogenetic protein subunits using a baculovirus expressionsystem. Biochem Biophys Res Commun209:859–866.
[21]. Israel DI, Nove J, Kerns KM, Kaufman RJ, Rosen V, Cox KA,Wozney JM1996Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and invivo. Growth Factors13:291–300.
[22]. Doucet C, Ernou I, Zhang Y, et al. Platelet lysates promote mesenchymal stemcell expansion: a safety substitute for animal serum in cell-based therapy applications.J Cell Physiol,2005,205(2):228-236.
[1] Catelas I, Sese N, Wu BM, et al. Human mesenchymal stem cell proliferation andosteogenic differentiation in fibrin gels in vitro[J].Tissue Eng,2006,12(8):2385.
[2] Koyama N, Okubo Y, Nakao K, Osawa K, Fujimura K, Bessho K2011Pluripotency of mesenchymal cells derived from synovial fluid in patients withtemporomandibular joint disorder. Biomaterials.33(1):80-90.
[3]柳向东，柴冈，李东，等。成人骨髓间充质干细胞的体外培养和表型鉴定，上海第二医科大学学报，200424:302-306.
[4] Woo SL, Hildebrand K, Watanabe N, Fenwick JA, Papageorgiou CD, Wang JH1999Tissue engineering of ligament and tendon healing. Clin Orthop Relat Res (367Suppl):S312-23.
[5] Turgeman G, Pittman DD, Müller R, Kurkalli BG, Zhou S, Pelled G, Peyser A,Zilberman Y, Moutsatsos IK, Gazit D2001Engineered human mesenchymal stemcells: a novel platform for skeletal cell mediated gene therapy. J Gene Med.May-Jun;3(3):240-51.
[6]Zhou H, Jin Z, Liu J, Yu S, Cui Q, Yi D2008Mesenchymal stem cells might beused to induce tolerance in heart transplantation. Med Hypotheses70(4):785-7.
[7] Lin W, Oh SK, Choo AB, George AJ. Activated T cells modulateimmunosuppression by embryonic-and bone marrow-derived mesenchymal stromalcells through a feedback mechanism. Cytotherapy.2012Mar;14(3):274-84.
[8] Tabuchi C. Bone deficit in ovariect om ized rats: Functionalcont ribution ofstromal cell populat ion and the ef fect of oral dihydrot achyst eol t reatment. J ClinInvest,1986,78:637.
[9] Sachs L. T he molecular cont rol of blood cells development.S cience,1987,238:1374-1379.
[10] Jaramillo-Ferrada P, Wolvetang E, Cooper-White J. Differential mesengenicpotential and expression of stem cell fate modulators in mesenchymal stromal cellsfrom human term placenta and bone marrow. J Cell Physiol.2011Nov21. doi:10.1002/jcp.24014.
[11] T abuchi C. Bone deficit in ovariect om ized rats: Functionalcont ribut ion of stromal cell populat ion and the ef fect of oral dihydrot achyst eol t reatment. J ClinInvest,1986,78:637.
[12] Egrise The number of fibroblastic colonies form ed f rom bone marrow isdecreased and the in vivo proliferation rat e of trabecular bone cells increased in agedrats Bone,1992,13:355.
[13]Kadiyala S.Culture expended canine mesenchymal stem cells possessosteochondrogenic potential in vivo and in vitro. Cell T rans,1997,6:125.
[14] Vaculik C, Schuster C, Bauer W, Iram N, Pfisterer K, Kramer G, Reinisch A,Strunk D, Elbe-Bürger A. Human dermis harbors distinct mesenchymal stromal cellsubsets. J Invest Dermatol.2012Mar;132(3Pt1):563-74.
[15] Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypicand functional comparison of cultures of marrow-derived mesenchymal stem cells(MSCs) and stromal cells. J Cell Physiol.1998;176:57-66.
[16] Lapi S, Nocchi F, Lamanna R, et al. Different media and supplements modulatethe clonogenic and expansion properties of rabbit bone marrow mesenchymal stemcells. BMC Res Notes.2008;1:53.
[1] RuberyPT.Enhaneing allograft bone healing through gene therapy.Spine，2010，35:1640-1647.
[2] Urist MR. Bone: formation by autoinduction.1965. Clin Orthop Relat Res.2002Feb;(395):4-10.
[3] Chung JH, Jeon HJ, Hong SY, Lee da L, Lee KH, Kim SH, Han YS, Manabe I,Miller YI, Lee SH. Palmitate promotes the paracrine effects of macrophages onvascular smooth muscle cells: the role of bone morphogenetic proteins. PLoS One.2012;7(2):e29100.
[4] Kuboki Y, Takita H. Bone morphogenetic protein (s)(BMP): structure and newfunctions. Clin Calcium.2003Apr;13(4):467-71.
[5] Blum JS, Barry MA, Mikos AG, Jansen JA. In vivo evaluation of gene therapyvectors in ex vivo-derived marrow stromal cells for bone regeneration in a ratcritical-size calvarial defect model. Hum Gene Ther.2003Dec10;14(18):1689-701.
[6]Zhu L, Chuanchang D, Wei L, Yilin C, Jiasheng D. Enhanced healing of goatfemur-defect using BMP7gene-modified BMSCs and load-bearing tissue-engineeredbone. J Orthop Res.2010;28:412-8.
[7] Urist MR. Bone: formation by autoinduction.1965. Clin Orthop Relat Res.2002Feb;(395):4-10.
[8] Rosen V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci.2006Apr;1068:19-25.[9] Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H,Tsukuda R, Sasaki S, Fujisawa Y1995Potent ectopic boneinducing activity of bonemorphogenetic protein-4/7heterodimer. Biochem Biophys Res Commun210:670–677.
[10] Simons DJ. Partial characterization of rat marrow stromal cells.Calcif Tissue INT,1991,48:326.
[11] Pitaru S. Basic fibroblast growth fac or enhances the capacity of rat stromal bonemarrow cells from mineralized bone like tissue inculture. J Bone Mineral Res Suppl2,1990,5: s78.
[12] CowanCM，Aghaloc T，ehouYF，et al..MieroCT Evaluation ofThree-Dimensional Mineralization in Response to BMP2Doses In Vitro and inCritieal Sized Rat Calvarial Defeets[J].TissueEng，2007，13(3):501一512.
[13] Lyons KM, Hogan BL, Robertson EJ1995Colocalization of BMP7and BMP2RNAs suggests that these factors cooperatively mediate tissue interactions duringmurine development. Mech Dev50:71–83.
[14] Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H,Tsukuda R, Sasaki S,Fujisawa Y1995Potent ectopic bone inducing activity of bone morphogeneticprotein-4/7heterodimer.Biochem Biophys Res Commun210:670–677.
[15] Stone CA. A molecular approach to bone regeneration. Br J Plast Surg.1997;50:369-73.
[16] Kübler N, Urist MR. Cell differentiation in response to partially purifiedosteosarcoma-derived bone morphogenetic protein in vivo and in vitro. Clin OrthopRelat Res.1993;(292):321-8.
[1] Gardner MJ, Demetrakopoulos D, Klepchick PR, Mooar PA. The efficacy ofautologous platelet gel in pain control and blood loss in total knee arthroplasty. Ananalysis of the haemoglobin, narcotic requirement and range of motion. Int Orthop.2007Jun;31(3):309-13.
[2] Berghoff WJ, Pietrzak WS, Rhodes RD. Platelet-rich plasma application during closurefollowing total knee arthroplasty. Orthopedics.2006Jul;29(7):590-8.
[3] Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights intoand novel applications for platelet-rich fibrin therapies. Trends Biotechnol.2006May;24(5):227-34.
[4] Cenni E, Savarino L, Perut F, Fotia C, Avnet S, Sabbioni G. Background andrationale of platelet gel in orthopaedic surgery. Musculoskelet Surg.2010May;94(1):1-8.
[5] Chang SH, Hsu YM, Wang YJ, Tsao YP, Tung KY, Wang TY. Fabrication ofpre-determined shape of bone segment with collagen-hydroxyapatite scaffold andautogenous platelet-rich plasma. J Mater Sci Mater Med.2009Jan;20(1):23-31.
[6]Sil ver FH, Wang MC, Pins GD. Preparation and use of fibrin glue in surgery. Biomaterials.1995Aug;16(12):891-903.
[7] Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as asource of proteins for healing and tissue regeneration. Thromb Haemost.2004Jan;91(1):4-15.
[8] Yamada Y, Ueda M, Naiki T, Takahashi M, Hata K, Nagasaka T. Autogenousinjectable bone for regeneration with mesenchymal stem cells and platelet-rich plasma:tissue-engineered bone regeneration. Tissue Eng.2004May-Jun;10(5-6):955-64.
[9] Tumbar T. Ontogeny and Homeostasis of Adult Epithelial Skin Stem Cells. StemCell Rev.2012Jan31.
[10] Ogino Y, Ayukawa Y, Kukita T, Koyano K. The contribution ofplatelet-derived growth factor, transforming growth factor-beta1, and insulin-likegrowth factor-I in platelet-rich plasma to the proliferation of osteoblast-like cells. OralSurg.2006Jun;101(6):724-9.
[11] Werner S, Grose R. Regulation of wound healing by growth factors andcytokines. Physiol Rev.2003Jul;83(3):835-70.
[12] Konya D, Gercek A, Akakin A, Akakin D, Tural S, Cetinel S, Ozgen S, PamirMN. The effects of inflammatory response associated with traumatic spinal cordinjury in cutaneous wound healing and on expression of transforming growthfactor-beta1(TGF-beta1) and platelet-derived growth factor (PDGF)-A at the woundsite in rats. Growth Factors.2008Apr;26(2):74-9.
[13] Mishra A, Woodall J Jr, Vieira A. Treatment of tendon and muscle usingplatelet-rich plasma. Clin Sports Med.2009Jan;28(1):113-25.
[14] Chen FM, Shelton RM, Jin Y, Chapple IL. Localized delivery of growth factors forperiodontal tissue regeneration: role, strategies, and perspectives. Med Res Rev.2009May;29(3):472-513.
[15] Griffin XL, Smith CM, Costa ML. The clinical use of platelet-rich plasma in the promotion ofbone healing: a systematic review. Injury.2009Feb;40(2):158-62.
[16] Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J BiolMed.2010Mar;83(1):1-9.
[17] Dominijanni A, Cristofaro MG, Brescia A, Giudice M. Platelet gel in oral andmaxillofacial surgery: a single-centre experience. Blood Transfus.2012Jan24:1-5.
[18] Dong Z, Li B, Liu B, Bai S, Li G, Ding A, Zhao J, Liu Y. Platelet-Rich PlasmaPromotes Angiogenesis of Prefabricated Vascularized Bone Graft. J Oral MaxillofacSurg.2012Feb25.
[19] Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Król W, Wielkoszynski T.Antibacterial effect of autologous platelet gel enriched with growth factors and otheractive substances: an in vitro study. J Bone Joint Surg Br.2007Mar;89(3):417-20.
[20] Yuan T, Zhang C, Zeng B. nt of chronic femoral osteomyelitis with platelet-richplasma (PRP): a case report. Transfus Apher Sci.2008Apr;38(2):167-73. Epub2008Mar17.
[21] Smith SE, Roukis TS.Bone and wound healing augmentation with platelet-rich plasma. ClinPodiatr Med Surg.2009Oct;26(4):559-88.
[22] Bettega G, Brun JP, Boutonnat J, Cracowski JL, Quesada JL, Hegelhofer H,Drillat P, Richard MJ. Autologous platelet concentrates for bone graft enhancement insinus lift procedure. Transfusion.2009Apr;49(4):779-85. Epub2009Jan2.
[23] Ogino Y, Ayukawa Y, Kukita T, Koyano K. The contribution of platelet-derivedgrowth factor, transforming growth factor-beta1, and insulin-like growth factor-I inplatelet-rich plasma to the proliferation of osteoblast-like cells. Oral Surg.2006Jun;101(6):724-9.
[24] Fernández-Barbero JE, Galindo-Moreno P, Avila-Ortiz G, et al. Flow cytometric andmorphological characterization of platelet-rich plasma gel. Clin Oral Implants Res2006;17:687-693.
[1] Dominijanni A, Cristofaro MG, Brescia A, Giudice M. Platelet gel in oral andmaxillofacial surgery: a single-centre experience. Blood Transfus.2012Jan24:1-5.
[2] Anitua E. Plasma rich in growth factors: preliminary results of use in thepreparation of future sites for implants. Int J Oral Maxillofac Implants.1999Jul-Aug;14(4):529-35.
[3] Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as asource of proteins for healing and tissue regeneration. Thromb Haemost.2004Jan;91(1):4-15.
[4] Yamada Y, Ueda M, Naiki T, Takahashi M, Hata K, Nagasaka T. Autogenousinjectable bone for regeneration with mesenchymal stem cells and platelet-rich plasma:tissue-engineered bone regeneration. Tissue Eng.2004May-Jun;10(5-6):955-64.
[5] Zhong J, Hu N, Xiong X, Lei Q, Li L. A novel promising therapy for skin aging:dermal multipotent stem cells against photoaged skin by activation of TGF-β/Smadand p38MAPK signaling pathway. Med Hypotheses.2011Mar;76(3):343-6.
[6] Ogino Y, Ayukawa Y, Kukita T, Koyano K. The contribution of platelet-derivedgrowth factor, transforming growth factor-beta1, and insulin-like growth factor-I inplatelet-rich plasma to the proliferation of osteoblast-like cells. Oral Surg.2006Jun;101(6):724-9.
[7] Smith SE, Roukis TS.Bone and wound healing augmentation with platelet-richplasma. Clin Podiatr Med Surg.2009Oct;26(4):559-88.
[8] Bettega G, Brun JP, Boutonnat J, Cracowski JL, Quesada JL, Hegelhofer H,Drillat P, Richard MJ. Autologous platelet concentrates for bone graft enhancement insinus lift procedure. Transfusion.2009Apr;49(4):779-85. Epub2009Jan2.
[9] Catelas I, Sese N, Wu BM, et al. Human mesenchymal stem cell proliferation andosteogenic differentiation in fibrin gels in vitro[J].Tissue Eng,2006,12(8):2385.
[10] Koyama N, Okubo Y, Nakao K, Osawa K, Fujimura K, Bessho K2011Pluripotency of mesenchymal cells derived from synovial fluid in patients withtemporomandibular joint disorder. Biomaterials.33(1):80-90.
[11]柳向东，柴冈，李东，等。成人骨髓间充质干细胞的体外培养和表型鉴定，上海第二医科大学学报，200424:302-306.
[12] Woo SL, Hildebrand K, Watanabe N, Fenwick JA, Papageorgiou CD, Wang JH1999Tissue engineering of ligament and tendon healing. Clin Orthop Relat Res (367Suppl):S312-23.
[13] Turgeman G, Pittman DD, Müller R, Kurkalli BG, Zhou S, Pelled G, Peyser A,Zilberman Y, Moutsatsos IK, Gazit D2001Engineered human mesenchymal stemcells: a novel platform for skeletal cell mediated gene therapy. J Gene Med.May-Jun;3(3):240-51.
[14] Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK,Piso P, Schlitt HJ, Dahlke MH. Mesenchymal stem cells can induce long-termacceptance of solid organ allografts in synergy with low-dose mycophenolate. TransplImmunol.2008Nov;20(1-2):55-60.
[15]Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,Grisanti S, Gianni AM2002Human bone marrow stromal cells suppressT-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood.99(10):3838-43.
[16] Fernández-Barbero JE, Galindo-Moreno P, Avila-Ortiz G, et al. Flow cytometricand morphological characterization of platelet-rich plasma gel. Clin Oral Implants Res2006;17:687-693.
[17]羊书勇，毛天球，程晓兵，等。富含血小板血浆凝胶结构用于组织工程载体可能性的扫描电镜观察。中国临床康复2005；9：114-115。
[18] Kim BS, Mooney DJ. Development of biocompatible synthetic extracellularmatrices for tissue engineering. Trends Biotechnol1998,16:224-233.
[1]. Housner JA, Jacobson JA, Misko R. Sonographically guided percutaneous needletenotomy for the treatment of chronic tendinosis. J Ultrasound Med2009;28:1187-1192
[2]. McShane JM, Nazarian LN, Harwood MI. Sonographically guided percutaneousneedle tenotomy for treatment of common extensor tendinosis in the elbow. JUltrasound Med2006;25:1281-1289
[3]. Rabago D, Best TM, Zgierska AE, Zeisig E, Ryan M, Crane D. A systematicreview of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol,whole blood and platelet-rich plasma.Br J Sports Med2009;43:471-481
[4]. Park EJ, Kim ES, Weber HP, Wright RF, Mooney DJ. Improved bone healing byangiogenic factorenriched platelet-rich plasma and its synergistic enhancement bybone morphogenetic protein-2.Int J Oral Maxillofac Implants2008;23:818-826
[5]. Schwarz A. New York Times Website. A promising treatment for athletes, inblood. In: The New York Times. Accessed December1,2010
[6]. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-richplasma: from basic science to clinical applications. Am J Sports Med2009;37:2259-2272
[7]. Wroblewski AP, Melia HJ, Wright VJ. Application of platelet-rich plasma toenhance tissue repair.Oper Tech Orthop2010;20:98-105
[8]. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR.Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg,1998;85:638-646
[9]. Marx R. Platelet-function: assays and events-introduction. Suppl ThrombHaemost1978;63:65-80
[10]. Anitua E. Plasma rich in growth factors: preliminary results of use in thepreparation of future sites for implants. Int J Oral Maxillofac Implants.1999Jul-Aug;14(4):529-35.[11]. de Mos M, van der Windt AE, Jahr H, et al. Canplatelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med2008;36:1171-1178
[12]. Lyras DN, Kazakos K, Agrogiannis G, et al. Experimental study of tendonhealing early phase: is IGF-1expression influenced by platelet rich plasma gel?Orthop Traumatol Surg Res2010;96:381-387
[13]. Everts PA, Knape JT, Weibrich G, et al. Plateletrich plasma and platelet gel: areview. J Extra Corpor Technol2006;38:174-187
[14]. Tidball JG. Inflammatory processes in muscle injury and repair. Am J PhysiolRegul Integr Comp Physiol2005;288:R345-R353
[15]. Lyras DN, Kazakos K, Verettas D, et al. The influenceof platelet-rich plasma on angiogenesis during the early phase of tendon healing. FootAnkle Int2009;30:1101-1106
[16]. Schnabel LV, Mohammed HO, Miller BJ, et al.Platelet rich plasma (PRP)enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. JOrthop Res2007;25:230-240
[17]. Smith SE, Roukis TS. Bone and wound healing augmentation with platelet-richplasma. Clin Podiatr Med Surg2009;26:559-588
[18]. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of plateletconcentrates: from pure platelet-rich plasma (P-PRP) to leucocyteand platelet-richfibrin (L-PRF). Trends Biotechnol2009;27:158-167
[19]. Cieslik-Bielecka A, Bielecki T, Gazdzik TS, Arendt J, Krol W, Szczepanski T.Autologous platelets and leukocytes can improve healing of infected high-energy softtissue injury. Transfus Apheresis Sci2009;41:9-12
[20]. Griffin XL, Smith CM, Costa ML. The clinical use of platelet-rich plasma in thepromotion of bone healing: a systematic review. Injury2009;40:158-162
[21]. Alsousou J, Thompson M, Hulley P, Noble A,Willett K. The biology ofplatelet-rich plasma and its application in trauma and orthopaedic surgery:a review ofthe literature. J Bone Joint Surg Br2009;91:987-996
[22]. Klein MB, Yalamanchi N, Pham H, Longaker MT, Chang J. Flexor tendonhealing in vitro: effects of TGF-beta on tendon cell collagen production.J Hand SurgAm2002;27:615-620
[23]. Chaput CD, Patel KV, Brindley GW, et al. Influence of a platelet concentrate onprosthetic bone ingrowth in a rabbit model. J Surg Orthop Adv2007;16:159-163
[24]. Tomoyasu A, Higashio K, Kanomata K, et al.Platelet-rich plasma stimulatesosteoblastic differentiation in the presence of BMPs. Biochem Biophys Res Commun2007;361:62-67
[25]. Kajikawa Y, Morihara T, Sakamoto H, et al. Platelet-rich plasma enhances theinitial mobilization of circulation-derived cells for tendon healing.
[26]. Jeong GK, Sandhu HS, Farmer J. Bone morphogenic proteins: applications inspinal surgery. HSS J2005;1:110-117
[27]. Field LD, Savoie FH. Common elbow injuries in sport. Sports Med1998;26:193-205
[28]. Tuite MJ, Kijowski R. Sports-related injuries of the elbow: an approach to MRIinterpretation.Clin Sports Med2006;25:387-408
[29]. Zeisig E, Ohberg L, Alfredson H. Extensor origin vascularity related to pain inpatients with tennis elbow. Knee Surg Sports Traumatol Arthrosc2006;14:659-663
[30]. Zeisig E, Fahlstrom M, Ohberg L, Alfredson H. A two-year sonographicfollow-up after intratendinous injection therapy in patients with tennis elbow.Br JSports Med2010;44:584-587
[31]. Kijowski R, De Smet AA. The role of ultrasound in the evaluation of sportsmedicine injuries of the upper extremity. Clin Sports Med2006;25:569-590
[32]. Levin D, Nazarian LN, Miller TT, et al. Lateral epicondylitis of the elbow: USfindings. Radiology2005;237:230-234
[33]. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with bufferedplatelet-rich plasma. Am J Sports Med2006;34:1774-1778
[34]. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T.Positive effect of an autologousplatelet concentrate in lateral epicondylitis in a double-blind randomized controlledtrial: platelet-rich plasma versus corticosteroid injection with a1-year follow-up. AmJ Sports Med2010;38:255-262
[35]. Goel DP, Chan D, Watson K, Mohtadi N. Safety and hospital costs of Achillestendon surgery: the serendipitous impact of a randomized clinical trial.Can J Surg2009;52:467-472
[36]. Paavola M, Kannus P, Jarvinen TA, Khan K, Jozsa L, Jarvinen M. Achillestendinopathy. J Bone Joint Surg Am2002;84-A:2062-2076
[37]. de Vos RJ, Weir A, van Schie HT, et al. Plateletrich plasma injection for chronicAchilles tendinopathy:a randomized controlled trial. JAMA2010;303:144-149
[38]. Rabago D, Wilson J, Zgierska A. Platelet-rich plasma for treatment of Achillestendinopathy.(letter and reply) JAMA2010;303:1696-1698
[39]. Kubo K, Yajima H, Takayama M, Ikebukuro T,Mizoguchi H, Takakura N.Effects of acupuncture and heating on blood volume and oxygen saturation of humanAchilles tendon in vivo. Eur J Appl Physiol2010;109:545-550
[40]. Glazer JL. An approach to the diagnosis and treatment of plantar fasciitis. PhysSportsmed2009;37:74-79
[41]. Jeswani T, Morlese J, McNally EG. Getting to the heel of the problem: plantarfascia lesions. Clin Radiol2009;64:931-939
[42]. McPoil TG, Martin RL, Cornwall MW, Wukich DK, Irrgang JJ, Godges JJ. Heelpain-plantar fasciitis:clinical practice guidelines linked to the internationalclassification of function, disability,and health from the orthopaedic section of theAmerican Physical Therapy Association. J Orthop Sports Phys Ther2008;38:A1-A18
[43]. Neufeld SK, Cerrato R. Plantar fasciitis: evaluation and treatment. J Am AcadOrthop Surg2008;16:338-346
[44]. Digiovanni BF, Nawoczenski DA, Malay DP, et al.Plantar fascia-specificstretching exercise improves outcomes in patients with chronic plantar fasciitis: aprospective clinical trial with two-year follow-up. J Bone Joint Surg Am2006;88:1775-1781
[45]. Donley BG, Moore T, Sferra J, Gozdanovic J,Smith R. The efficacy of oralnonsteroidal anti-inflammatory medication (NSAID) in the treatment of plantarfasciitis: a randomized, prospective,placebo-controlled study. Foot Ankle Int2007;28:20-23
[46]. Hyland MR, Webber-Gaffney A, Cohen L, Lichtman PT. Randomized controlledtrial of calcaneal taping, sham taping, and plantar fascia stretching for the short-termmanagement of plantar heel pain.J Orthop Sports Phys Ther2006;36:364-371
[47]. Lemont H, Ammirati KM, Usen N. Plantar fasciitis:a degenerative process(fasciosis) without inflammation.J Am Podiatr Med Assoc2003;93:234-237
[48]. Zanetti M, Metzdorf A, Kundert HP, et al. Achilles tendons: clinical relevance ofneovascularization diagnosed with power Doppler US. Radiology2003;227:556-560
[49]. Hartgerink P, Fessell DP, Jacobson JA, van Holsbeeck MT. Full-versuspartial-thickness Achilles tendon tears: sonographic accuracy and characterization in26cases with surgical correlation.Radiology2001;220:406-412
[50]. Filardo G, Kon E, Della Villa S, Vincentelli F,Fornasari PM, Marcacci M. Use ofplatelet-rich plasma for the treatment of refractory jumper’s knee. Int Orthop2010;34:909-915
[51]. Kalaci A, Cakici H, Hapa O, Yanat AN, Dogramaci Y, Sevinc TT. Treatment ofplantar fasciitis using four different local injection modalities: a randomizedprospective clinical trial. J Am Podiatr Med Assoc2009;99:108-113
[52]. Barrett SL, Erredge SE. Growth factors for chronic plantar fasciitis. PodiatryToday2004;17:37-42
[53]. Aspenberg P, Virchenko O. Platelet concentrate injection improves Achillestendon repair in rats.Acta Orthop Scand2004;75:93-99
[54]. Virchenko O, Aspenberg P. How can one platelet injection after tendon injurylead to a stronger tendon after4weeks? Interplay between early regeneration andmechanical stimulation. Acta Orthop2006;77:806-812
[55]. Frei R, Biosca FE, Handl M, Trc T. Conservative treatment using plasma rich ingrowth factors(PRGF) for injury to the ligamentous complex of the ankle [in Czech].Acta Chir Orthop Traumatol Cech2008;75:28-33
[56]. Clanton TO, Paul P. Syndesmosis injuries in athletes.Foot Ankle Clin2002;7:529-549
[57]. Malliaropoulos N, Papacostas E, Kiritsi O, et al.Posterior thigh muscle injuriesin elite track and field athletes. Am J Sports Med2010;38:1813-1819
[58]. Orchard J, Best TM. The management of muscle strain injuries: an early returnversus the risk of recurrence. Clin J Sport Med2002;12:3-5
[59]. Alfredson H, Lorentzon R. Chronic Achilles tendinosis:recommendations fortreatment and prevention.Sports Med2000;29:135-146
[60]. Armfield DR, Kim DH, Towers JD, Bradley JP, Robertson DD. Sports-relatedmuscle injury in the lower extremity. Clin Sports Med2006;25:803-842
[61]. Liu Y, Kalen A, Risto O, Wahlstrom O. Fibroblast proliferation due to exposureto a platelet concentrate in vitro is pH dependent. Wound Repair Regen2002;10:336-340
[62]. Smith C, Kruger MJ, Smith RM, Myburgh KH.The inflammatory response toskeletal muscle injury:illuminating complexities. Sports Med2008;38:947-969
[63]. Toumi H, Best TM. The inflammatory response:friend or enemy for muscleinjury? Br J Sports Med2003;37:284-286
[64]. Dohan DM, Choukroun J, Diss A, et al. Plateletrich fibrin (PRF):asecond-generation platelet concentrate. Part III. Leucocyte activation: a new featurefor platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod2006;101:e51-e55
[2]. Catelas I, Sese N, Wu BM, et al. Human mesenchymal stem cell proliferation andosteogenic differentiation in fibrin gels in vitro[J].Tissue Eng,2006,12(8):2385.
[3]. Koyama N, Okubo Y, Nakao K, Osawa K, Fujimura K, Bessho K2011Pluripotency of mesenchymal cells derived from synovial fluid in patients withtemporomandibular joint disorder. Biomaterials.33(1):80-90.
[4].柳向东，柴冈，李东，等。成人骨髓间充质干细胞的体外培养和表型鉴定，上海第二医科大学学报，200424:302-306.
[5]. Woo SL, Hildebrand K, Watanabe N, Fenwick JA, Papageorgiou CD, Wang JH1999Tissue engineering of ligament and tendon healing. Clin Orthop Relat Res (367Suppl):S312-23.
[6]. Turgeman G, Pittman DD, Müller R, Kurkalli BG, Zhou S, Pelled G, Peyser A,Zilberman Y, Moutsatsos IK, Gazit D2001Engineered human mesenchymal stemcells: a novel platform for skeletal cell mediated gene therapy. J Gene Med.May-Jun;3(3):240-51.
[7]. Zhou H, Jin Z, Liu J, Yu S, Cui Q, Yi D2008Mesenchymal stem cells might beused to induce tolerance in heart transplantation. Med Hypotheses70(4):785-7.
[8]. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,Grisanti S, Gianni AM2002Human bone marrow stromal cells suppressT-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood.99(10):3838-43.
[9]. Kovacs K，Velich N，HuszarT，et a1．Mistomorphometric and densitometricevaluation of the effects of platelet-rich plasma on the remodeling of beta-tricalciumphosphate in beagle dogs[J]．J Craniofae Surg，2005，16(1)：l50．
[10]. Lucarelli E, Beccheroni A, Donati D, et al. Platelet-derived growth factorsenhance proliferation of human stromal stem cells[J]. Biomaterials2003,24(18):3095.
[11]. FuerstG,Reinhard G,TanglS,et al.Effect of platelet-released growth factors andcollagen type I on osseous regeneration of mandibular defects[J]. J ClinPeriodontol,2004,31(9):784.
[12].羊书勇,毛天球,程晓兵,等。富含血小板血浆凝胶结构用于组织工程载体可能性的扫描电镜观察，中国临床康复,2005,9(26):114-115.
[13].Kim BS, Mooney DJ. Development of biocompatible synthetic extracellularmatrices for tissue engineering [J]. Trends Biotechnol,1998,16(5):224-233.
[14]. Urist MR1965Bone: Formation by autoinduction. Science150:893–899.
[15]. Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, Sibley BS,Wozney JM1988Purification and characterization of other distinct bone-inducingfactors. Proc Natl Acad Sci USA85:9484–9488.
[16]. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, HewickRM, Wang EA1988Novel regulators of bone formation: Molecular clones andactivities. Science242:1528–1534.
[17]. Sampath TK, Coughlin JE, Whetstone RM, Banach D, Corbett C, Ridge RJ,Ozkaynak E, Oppermann H, Rueger DC1990Bovine osteogenic protein is composedof dimers of OP-1and BMP-2A, two members of the transforming growth factor-betasuperfamily. J Biol Chem265:13198–13205.
[18]. Ozkaynak E, Rueger DC, Drier EA, Corbett C, Ridge RJ, Sampath TK,Oppermann H1990OP-1cDNA encodes an osteogenic protein in the TGF-betafamily. EMBO J9:2085–2093.
[19]. Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H, Tsukuda R, Sasaki S,Fujisawa Y1995Potent ectopic boneinducing activity of bone morphogeneticprotein-4/7heterodimer. Biochem Biophys Res Commun210:670–677.
[20]. Hazama M, Aono A, Ueno N, Fujisawa Y1995Efficient expression of aheterodimer of bone morphogenetic protein subunits using a baculovirus expressionsystem. Biochem Biophys Res Commun209:859–866.
[21]. Israel DI, Nove J, Kerns KM, Kaufman RJ, Rosen V, Cox KA,Wozney JM1996Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and invivo. Growth Factors13:291–300.
[22]. Doucet C, Ernou I, Zhang Y, et al. Platelet lysates promote mesenchymal stemcell expansion: a safety substitute for animal serum in cell-based therapy applications.J Cell Physiol,2005,205(2):228-236.
[1] Catelas I, Sese N, Wu BM, et al. Human mesenchymal stem cell proliferation andosteogenic differentiation in fibrin gels in vitro[J].Tissue Eng,2006,12(8):2385.
[2] Koyama N, Okubo Y, Nakao K, Osawa K, Fujimura K, Bessho K2011Pluripotency of mesenchymal cells derived from synovial fluid in patients withtemporomandibular joint disorder. Biomaterials.33(1):80-90.
[3]柳向东，柴冈，李东，等。成人骨髓间充质干细胞的体外培养和表型鉴定，上海第二医科大学学报，200424:302-306.
[4] Woo SL, Hildebrand K, Watanabe N, Fenwick JA, Papageorgiou CD, Wang JH1999Tissue engineering of ligament and tendon healing. Clin Orthop Relat Res (367Suppl):S312-23.
[5] Turgeman G, Pittman DD, Müller R, Kurkalli BG, Zhou S, Pelled G, Peyser A,Zilberman Y, Moutsatsos IK, Gazit D2001Engineered human mesenchymal stemcells: a novel platform for skeletal cell mediated gene therapy. J Gene Med.May-Jun;3(3):240-51.
[6]Zhou H, Jin Z, Liu J, Yu S, Cui Q, Yi D2008Mesenchymal stem cells might beused to induce tolerance in heart transplantation. Med Hypotheses70(4):785-7.
[7] Lin W, Oh SK, Choo AB, George AJ. Activated T cells modulateimmunosuppression by embryonic-and bone marrow-derived mesenchymal stromalcells through a feedback mechanism. Cytotherapy.2012Mar;14(3):274-84.
[8] Tabuchi C. Bone deficit in ovariect om ized rats: Functionalcont ribution ofstromal cell populat ion and the ef fect of oral dihydrot achyst eol t reatment. J ClinInvest,1986,78:637.
[9] Sachs L. T he molecular cont rol of blood cells development.S cience,1987,238:1374-1379.
[10] Jaramillo-Ferrada P, Wolvetang E, Cooper-White J. Differential mesengenicpotential and expression of stem cell fate modulators in mesenchymal stromal cellsfrom human term placenta and bone marrow. J Cell Physiol.2011Nov21. doi:10.1002/jcp.24014.
[11] T abuchi C. Bone deficit in ovariect om ized rats: Functionalcont ribut ion of stromal cell populat ion and the ef fect of oral dihydrot achyst eol t reatment. J ClinInvest,1986,78:637.
[12] Egrise The number of fibroblastic colonies form ed f rom bone marrow isdecreased and the in vivo proliferation rat e of trabecular bone cells increased in agedrats Bone,1992,13:355.
[13]Kadiyala S.Culture expended canine mesenchymal stem cells possessosteochondrogenic potential in vivo and in vitro. Cell T rans,1997,6:125.
[14] Vaculik C, Schuster C, Bauer W, Iram N, Pfisterer K, Kramer G, Reinisch A,Strunk D, Elbe-Bürger A. Human dermis harbors distinct mesenchymal stromal cellsubsets. J Invest Dermatol.2012Mar;132(3Pt1):563-74.
[15] Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypicand functional comparison of cultures of marrow-derived mesenchymal stem cells(MSCs) and stromal cells. J Cell Physiol.1998;176:57-66.
[16] Lapi S, Nocchi F, Lamanna R, et al. Different media and supplements modulatethe clonogenic and expansion properties of rabbit bone marrow mesenchymal stemcells. BMC Res Notes.2008;1:53.
[1] RuberyPT.Enhaneing allograft bone healing through gene therapy.Spine，2010，35:1640-1647.
[2] Urist MR. Bone: formation by autoinduction.1965. Clin Orthop Relat Res.2002Feb;(395):4-10.
[3] Chung JH, Jeon HJ, Hong SY, Lee da L, Lee KH, Kim SH, Han YS, Manabe I,Miller YI, Lee SH. Palmitate promotes the paracrine effects of macrophages onvascular smooth muscle cells: the role of bone morphogenetic proteins. PLoS One.2012;7(2):e29100.
[4] Kuboki Y, Takita H. Bone morphogenetic protein (s)(BMP): structure and newfunctions. Clin Calcium.2003Apr;13(4):467-71.
[5] Blum JS, Barry MA, Mikos AG, Jansen JA. In vivo evaluation of gene therapyvectors in ex vivo-derived marrow stromal cells for bone regeneration in a ratcritical-size calvarial defect model. Hum Gene Ther.2003Dec10;14(18):1689-701.
[6]Zhu L, Chuanchang D, Wei L, Yilin C, Jiasheng D. Enhanced healing of goatfemur-defect using BMP7gene-modified BMSCs and load-bearing tissue-engineeredbone. J Orthop Res.2010;28:412-8.
[7] Urist MR. Bone: formation by autoinduction.1965. Clin Orthop Relat Res.2002Feb;(395):4-10.
[8] Rosen V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci.2006Apr;1068:19-25.[9] Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H,Tsukuda R, Sasaki S, Fujisawa Y1995Potent ectopic boneinducing activity of bonemorphogenetic protein-4/7heterodimer. Biochem Biophys Res Commun210:670–677.
[10] Simons DJ. Partial characterization of rat marrow stromal cells.Calcif Tissue INT,1991,48:326.
[11] Pitaru S. Basic fibroblast growth fac or enhances the capacity of rat stromal bonemarrow cells from mineralized bone like tissue inculture. J Bone Mineral Res Suppl2,1990,5: s78.
[12] CowanCM，Aghaloc T，ehouYF，et al..MieroCT Evaluation ofThree-Dimensional Mineralization in Response to BMP2Doses In Vitro and inCritieal Sized Rat Calvarial Defeets[J].TissueEng，2007，13(3):501一512.
[13] Lyons KM, Hogan BL, Robertson EJ1995Colocalization of BMP7and BMP2RNAs suggests that these factors cooperatively mediate tissue interactions duringmurine development. Mech Dev50:71–83.
[14] Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H,Tsukuda R, Sasaki S,Fujisawa Y1995Potent ectopic bone inducing activity of bone morphogeneticprotein-4/7heterodimer.Biochem Biophys Res Commun210:670–677.
[15] Stone CA. A molecular approach to bone regeneration. Br J Plast Surg.1997;50:369-73.
[16] Kübler N, Urist MR. Cell differentiation in response to partially purifiedosteosarcoma-derived bone morphogenetic protein in vivo and in vitro. Clin OrthopRelat Res.1993;(292):321-8.
[1] Gardner MJ, Demetrakopoulos D, Klepchick PR, Mooar PA. The efficacy ofautologous platelet gel in pain control and blood loss in total knee arthroplasty. Ananalysis of the haemoglobin, narcotic requirement and range of motion. Int Orthop.2007Jun;31(3):309-13.
[2] Berghoff WJ, Pietrzak WS, Rhodes RD. Platelet-rich plasma application during closurefollowing total knee arthroplasty. Orthopedics.2006Jul;29(7):590-8.
[3] Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights intoand novel applications for platelet-rich fibrin therapies. Trends Biotechnol.2006May;24(5):227-34.
[4] Cenni E, Savarino L, Perut F, Fotia C, Avnet S, Sabbioni G. Background andrationale of platelet gel in orthopaedic surgery. Musculoskelet Surg.2010May;94(1):1-8.
[5] Chang SH, Hsu YM, Wang YJ, Tsao YP, Tung KY, Wang TY. Fabrication ofpre-determined shape of bone segment with collagen-hydroxyapatite scaffold andautogenous platelet-rich plasma. J Mater Sci Mater Med.2009Jan;20(1):23-31.
[6]Sil ver FH, Wang MC, Pins GD. Preparation and use of fibrin glue in surgery. Biomaterials.1995Aug;16(12):891-903.
[7] Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as asource of proteins for healing and tissue regeneration. Thromb Haemost.2004Jan;91(1):4-15.
[8] Yamada Y, Ueda M, Naiki T, Takahashi M, Hata K, Nagasaka T. Autogenousinjectable bone for regeneration with mesenchymal stem cells and platelet-rich plasma:tissue-engineered bone regeneration. Tissue Eng.2004May-Jun;10(5-6):955-64.
[9] Tumbar T. Ontogeny and Homeostasis of Adult Epithelial Skin Stem Cells. StemCell Rev.2012Jan31.
[10] Ogino Y, Ayukawa Y, Kukita T, Koyano K. The contribution ofplatelet-derived growth factor, transforming growth factor-beta1, and insulin-likegrowth factor-I in platelet-rich plasma to the proliferation of osteoblast-like cells. OralSurg.2006Jun;101(6):724-9.
[11] Werner S, Grose R. Regulation of wound healing by growth factors andcytokines. Physiol Rev.2003Jul;83(3):835-70.
[12] Konya D, Gercek A, Akakin A, Akakin D, Tural S, Cetinel S, Ozgen S, PamirMN. The effects of inflammatory response associated with traumatic spinal cordinjury in cutaneous wound healing and on expression of transforming growthfactor-beta1(TGF-beta1) and platelet-derived growth factor (PDGF)-A at the woundsite in rats. Growth Factors.2008Apr;26(2):74-9.
[13] Mishra A, Woodall J Jr, Vieira A. Treatment of tendon and muscle usingplatelet-rich plasma. Clin Sports Med.2009Jan;28(1):113-25.
[14] Chen FM, Shelton RM, Jin Y, Chapple IL. Localized delivery of growth factors forperiodontal tissue regeneration: role, strategies, and perspectives. Med Res Rev.2009May;29(3):472-513.
[15] Griffin XL, Smith CM, Costa ML. The clinical use of platelet-rich plasma in the promotion ofbone healing: a systematic review. Injury.2009Feb;40(2):158-62.
[16] Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J BiolMed.2010Mar;83(1):1-9.
[17] Dominijanni A, Cristofaro MG, Brescia A, Giudice M. Platelet gel in oral andmaxillofacial surgery: a single-centre experience. Blood Transfus.2012Jan24:1-5.
[18] Dong Z, Li B, Liu B, Bai S, Li G, Ding A, Zhao J, Liu Y. Platelet-Rich PlasmaPromotes Angiogenesis of Prefabricated Vascularized Bone Graft. J Oral MaxillofacSurg.2012Feb25.
[19] Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Król W, Wielkoszynski T.Antibacterial effect of autologous platelet gel enriched with growth factors and otheractive substances: an in vitro study. J Bone Joint Surg Br.2007Mar;89(3):417-20.
[20] Yuan T, Zhang C, Zeng B. nt of chronic femoral osteomyelitis with platelet-richplasma (PRP): a case report. Transfus Apher Sci.2008Apr;38(2):167-73. Epub2008Mar17.
[21] Smith SE, Roukis TS.Bone and wound healing augmentation with platelet-rich plasma. ClinPodiatr Med Surg.2009Oct;26(4):559-88.
[22] Bettega G, Brun JP, Boutonnat J, Cracowski JL, Quesada JL, Hegelhofer H,Drillat P, Richard MJ. Autologous platelet concentrates for bone graft enhancement insinus lift procedure. Transfusion.2009Apr;49(4):779-85. Epub2009Jan2.
[23] Ogino Y, Ayukawa Y, Kukita T, Koyano K. The contribution of platelet-derivedgrowth factor, transforming growth factor-beta1, and insulin-like growth factor-I inplatelet-rich plasma to the proliferation of osteoblast-like cells. Oral Surg.2006Jun;101(6):724-9.
[24] Fernández-Barbero JE, Galindo-Moreno P, Avila-Ortiz G, et al. Flow cytometric andmorphological characterization of platelet-rich plasma gel. Clin Oral Implants Res2006;17:687-693.
[1] Dominijanni A, Cristofaro MG, Brescia A, Giudice M. Platelet gel in oral andmaxillofacial surgery: a single-centre experience. Blood Transfus.2012Jan24:1-5.
[2] Anitua E. Plasma rich in growth factors: preliminary results of use in thepreparation of future sites for implants. Int J Oral Maxillofac Implants.1999Jul-Aug;14(4):529-35.
[3] Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as asource of proteins for healing and tissue regeneration. Thromb Haemost.2004Jan;91(1):4-15.
[4] Yamada Y, Ueda M, Naiki T, Takahashi M, Hata K, Nagasaka T. Autogenousinjectable bone for regeneration with mesenchymal stem cells and platelet-rich plasma:tissue-engineered bone regeneration. Tissue Eng.2004May-Jun;10(5-6):955-64.
[5] Zhong J, Hu N, Xiong X, Lei Q, Li L. A novel promising therapy for skin aging:dermal multipotent stem cells against photoaged skin by activation of TGF-β/Smadand p38MAPK signaling pathway. Med Hypotheses.2011Mar;76(3):343-6.
[6] Ogino Y, Ayukawa Y, Kukita T, Koyano K. The contribution of platelet-derivedgrowth factor, transforming growth factor-beta1, and insulin-like growth factor-I inplatelet-rich plasma to the proliferation of osteoblast-like cells. Oral Surg.2006Jun;101(6):724-9.
[7] Smith SE, Roukis TS.Bone and wound healing augmentation with platelet-richplasma. Clin Podiatr Med Surg.2009Oct;26(4):559-88.
[8] Bettega G, Brun JP, Boutonnat J, Cracowski JL, Quesada JL, Hegelhofer H,Drillat P, Richard MJ. Autologous platelet concentrates for bone graft enhancement insinus lift procedure. Transfusion.2009Apr;49(4):779-85. Epub2009Jan2.
[9] Catelas I, Sese N, Wu BM, et al. Human mesenchymal stem cell proliferation andosteogenic differentiation in fibrin gels in vitro[J].Tissue Eng,2006,12(8):2385.
[10] Koyama N, Okubo Y, Nakao K, Osawa K, Fujimura K, Bessho K2011Pluripotency of mesenchymal cells derived from synovial fluid in patients withtemporomandibular joint disorder. Biomaterials.33(1):80-90.
[11]柳向东，柴冈，李东，等。成人骨髓间充质干细胞的体外培养和表型鉴定，上海第二医科大学学报，200424:302-306.
[12] Woo SL, Hildebrand K, Watanabe N, Fenwick JA, Papageorgiou CD, Wang JH1999Tissue engineering of ligament and tendon healing. Clin Orthop Relat Res (367Suppl):S312-23.
[13] Turgeman G, Pittman DD, Müller R, Kurkalli BG, Zhou S, Pelled G, Peyser A,Zilberman Y, Moutsatsos IK, Gazit D2001Engineered human mesenchymal stemcells: a novel platform for skeletal cell mediated gene therapy. J Gene Med.May-Jun;3(3):240-51.
[14] Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK,Piso P, Schlitt HJ, Dahlke MH. Mesenchymal stem cells can induce long-termacceptance of solid organ allografts in synergy with low-dose mycophenolate. TransplImmunol.2008Nov;20(1-2):55-60.
[15]Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,Grisanti S, Gianni AM2002Human bone marrow stromal cells suppressT-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood.99(10):3838-43.
[16] Fernández-Barbero JE, Galindo-Moreno P, Avila-Ortiz G, et al. Flow cytometricand morphological characterization of platelet-rich plasma gel. Clin Oral Implants Res2006;17:687-693.
[17]羊书勇，毛天球，程晓兵，等。富含血小板血浆凝胶结构用于组织工程载体可能性的扫描电镜观察。中国临床康复2005；9：114-115。
[18] Kim BS, Mooney DJ. Development of biocompatible synthetic extracellularmatrices for tissue engineering. Trends Biotechnol1998,16:224-233.
[1]. Housner JA, Jacobson JA, Misko R. Sonographically guided percutaneous needletenotomy for the treatment of chronic tendinosis. J Ultrasound Med2009;28:1187-1192
[2]. McShane JM, Nazarian LN, Harwood MI. Sonographically guided percutaneousneedle tenotomy for treatment of common extensor tendinosis in the elbow. JUltrasound Med2006;25:1281-1289
[3]. Rabago D, Best TM, Zgierska AE, Zeisig E, Ryan M, Crane D. A systematicreview of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol,whole blood and platelet-rich plasma.Br J Sports Med2009;43:471-481
[4]. Park EJ, Kim ES, Weber HP, Wright RF, Mooney DJ. Improved bone healing byangiogenic factorenriched platelet-rich plasma and its synergistic enhancement bybone morphogenetic protein-2.Int J Oral Maxillofac Implants2008;23:818-826
[5]. Schwarz A. New York Times Website. A promising treatment for athletes, inblood. In: The New York Times. Accessed December1,2010
[6]. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-richplasma: from basic science to clinical applications. Am J Sports Med2009;37:2259-2272
[7]. Wroblewski AP, Melia HJ, Wright VJ. Application of platelet-rich plasma toenhance tissue repair.Oper Tech Orthop2010;20:98-105
[8]. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR.Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg,1998;85:638-646
[9]. Marx R. Platelet-function: assays and events-introduction. Suppl ThrombHaemost1978;63:65-80
[10]. Anitua E. Plasma rich in growth factors: preliminary results of use in thepreparation of future sites for implants. Int J Oral Maxillofac Implants.1999Jul-Aug;14(4):529-35.[11]. de Mos M, van der Windt AE, Jahr H, et al. Canplatelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med2008;36:1171-1178
[12]. Lyras DN, Kazakos K, Agrogiannis G, et al. Experimental study of tendonhealing early phase: is IGF-1expression influenced by platelet rich plasma gel?Orthop Traumatol Surg Res2010;96:381-387
[13]. Everts PA, Knape JT, Weibrich G, et al. Plateletrich plasma and platelet gel: areview. J Extra Corpor Technol2006;38:174-187
[14]. Tidball JG. Inflammatory processes in muscle injury and repair. Am J PhysiolRegul Integr Comp Physiol2005;288:R345-R353
[15]. Lyras DN, Kazakos K, Verettas D, et al. The influenceof platelet-rich plasma on angiogenesis during the early phase of tendon healing. FootAnkle Int2009;30:1101-1106
[16]. Schnabel LV, Mohammed HO, Miller BJ, et al.Platelet rich plasma (PRP)enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. JOrthop Res2007;25:230-240
[17]. Smith SE, Roukis TS. Bone and wound healing augmentation with platelet-richplasma. Clin Podiatr Med Surg2009;26:559-588
[18]. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of plateletconcentrates: from pure platelet-rich plasma (P-PRP) to leucocyteand platelet-richfibrin (L-PRF). Trends Biotechnol2009;27:158-167
[19]. Cieslik-Bielecka A, Bielecki T, Gazdzik TS, Arendt J, Krol W, Szczepanski T.Autologous platelets and leukocytes can improve healing of infected high-energy softtissue injury. Transfus Apheresis Sci2009;41:9-12
[20]. Griffin XL, Smith CM, Costa ML. The clinical use of platelet-rich plasma in thepromotion of bone healing: a systematic review. Injury2009;40:158-162
[21]. Alsousou J, Thompson M, Hulley P, Noble A,Willett K. The biology ofplatelet-rich plasma and its application in trauma and orthopaedic surgery:a review ofthe literature. J Bone Joint Surg Br2009;91:987-996
[22]. Klein MB, Yalamanchi N, Pham H, Longaker MT, Chang J. Flexor tendonhealing in vitro: effects of TGF-beta on tendon cell collagen production.J Hand SurgAm2002;27:615-620
[23]. Chaput CD, Patel KV, Brindley GW, et al. Influence of a platelet concentrate onprosthetic bone ingrowth in a rabbit model. J Surg Orthop Adv2007;16:159-163
[24]. Tomoyasu A, Higashio K, Kanomata K, et al.Platelet-rich plasma stimulatesosteoblastic differentiation in the presence of BMPs. Biochem Biophys Res Commun2007;361:62-67
[25]. Kajikawa Y, Morihara T, Sakamoto H, et al. Platelet-rich plasma enhances theinitial mobilization of circulation-derived cells for tendon healing.
[26]. Jeong GK, Sandhu HS, Farmer J. Bone morphogenic proteins: applications inspinal surgery. HSS J2005;1:110-117
[27]. Field LD, Savoie FH. Common elbow injuries in sport. Sports Med1998;26:193-205
[28]. Tuite MJ, Kijowski R. Sports-related injuries of the elbow: an approach to MRIinterpretation.Clin Sports Med2006;25:387-408
[29]. Zeisig E, Ohberg L, Alfredson H. Extensor origin vascularity related to pain inpatients with tennis elbow. Knee Surg Sports Traumatol Arthrosc2006;14:659-663
[30]. Zeisig E, Fahlstrom M, Ohberg L, Alfredson H. A two-year sonographicfollow-up after intratendinous injection therapy in patients with tennis elbow.Br JSports Med2010;44:584-587
[31]. Kijowski R, De Smet AA. The role of ultrasound in the evaluation of sportsmedicine injuries of the upper extremity. Clin Sports Med2006;25:569-590
[32]. Levin D, Nazarian LN, Miller TT, et al. Lateral epicondylitis of the elbow: USfindings. Radiology2005;237:230-234
[33]. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with bufferedplatelet-rich plasma. Am J Sports Med2006;34:1774-1778
[34]. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T.Positive effect of an autologousplatelet concentrate in lateral epicondylitis in a double-blind randomized controlledtrial: platelet-rich plasma versus corticosteroid injection with a1-year follow-up. AmJ Sports Med2010;38:255-262
[35]. Goel DP, Chan D, Watson K, Mohtadi N. Safety and hospital costs of Achillestendon surgery: the serendipitous impact of a randomized clinical trial.Can J Surg2009;52:467-472
[36]. Paavola M, Kannus P, Jarvinen TA, Khan K, Jozsa L, Jarvinen M. Achillestendinopathy. J Bone Joint Surg Am2002;84-A:2062-2076
[37]. de Vos RJ, Weir A, van Schie HT, et al. Plateletrich plasma injection for chronicAchilles tendinopathy:a randomized controlled trial. JAMA2010;303:144-149
[38]. Rabago D, Wilson J, Zgierska A. Platelet-rich plasma for treatment of Achillestendinopathy.(letter and reply) JAMA2010;303:1696-1698
[39]. Kubo K, Yajima H, Takayama M, Ikebukuro T,Mizoguchi H, Takakura N.Effects of acupuncture and heating on blood volume and oxygen saturation of humanAchilles tendon in vivo. Eur J Appl Physiol2010;109:545-550
[40]. Glazer JL. An approach to the diagnosis and treatment of plantar fasciitis. PhysSportsmed2009;37:74-79
[41]. Jeswani T, Morlese J, McNally EG. Getting to the heel of the problem: plantarfascia lesions. Clin Radiol2009;64:931-939
[42]. McPoil TG, Martin RL, Cornwall MW, Wukich DK, Irrgang JJ, Godges JJ. Heelpain-plantar fasciitis:clinical practice guidelines linked to the internationalclassification of function, disability,and health from the orthopaedic section of theAmerican Physical Therapy Association. J Orthop Sports Phys Ther2008;38:A1-A18
[43]. Neufeld SK, Cerrato R. Plantar fasciitis: evaluation and treatment. J Am AcadOrthop Surg2008;16:338-346
[44]. Digiovanni BF, Nawoczenski DA, Malay DP, et al.Plantar fascia-specificstretching exercise improves outcomes in patients with chronic plantar fasciitis: aprospective clinical trial with two-year follow-up. J Bone Joint Surg Am2006;88:1775-1781
[45]. Donley BG, Moore T, Sferra J, Gozdanovic J,Smith R. The efficacy of oralnonsteroidal anti-inflammatory medication (NSAID) in the treatment of plantarfasciitis: a randomized, prospective,placebo-controlled study. Foot Ankle Int2007;28:20-23
[46]. Hyland MR, Webber-Gaffney A, Cohen L, Lichtman PT. Randomized controlledtrial of calcaneal taping, sham taping, and plantar fascia stretching for the short-termmanagement of plantar heel pain.J Orthop Sports Phys Ther2006;36:364-371
[47]. Lemont H, Ammirati KM, Usen N. Plantar fasciitis:a degenerative process(fasciosis) without inflammation.J Am Podiatr Med Assoc2003;93:234-237
[48]. Zanetti M, Metzdorf A, Kundert HP, et al. Achilles tendons: clinical relevance ofneovascularization diagnosed with power Doppler US. Radiology2003;227:556-560
[49]. Hartgerink P, Fessell DP, Jacobson JA, van Holsbeeck MT. Full-versuspartial-thickness Achilles tendon tears: sonographic accuracy and characterization in26cases with surgical correlation.Radiology2001;220:406-412
[50]. Filardo G, Kon E, Della Villa S, Vincentelli F,Fornasari PM, Marcacci M. Use ofplatelet-rich plasma for the treatment of refractory jumper’s knee. Int Orthop2010;34:909-915
[51]. Kalaci A, Cakici H, Hapa O, Yanat AN, Dogramaci Y, Sevinc TT. Treatment ofplantar fasciitis using four different local injection modalities: a randomizedprospective clinical trial. J Am Podiatr Med Assoc2009;99:108-113
[52]. Barrett SL, Erredge SE. Growth factors for chronic plantar fasciitis. PodiatryToday2004;17:37-42
[53]. Aspenberg P, Virchenko O. Platelet concentrate injection improves Achillestendon repair in rats.Acta Orthop Scand2004;75:93-99
[54]. Virchenko O, Aspenberg P. How can one platelet injection after tendon injurylead to a stronger tendon after4weeks? Interplay between early regeneration andmechanical stimulation. Acta Orthop2006;77:806-812
[55]. Frei R, Biosca FE, Handl M, Trc T. Conservative treatment using plasma rich ingrowth factors(PRGF) for injury to the ligamentous complex of the ankle [in Czech].Acta Chir Orthop Traumatol Cech2008;75:28-33
[56]. Clanton TO, Paul P. Syndesmosis injuries in athletes.Foot Ankle Clin2002;7:529-549
[57]. Malliaropoulos N, Papacostas E, Kiritsi O, et al.Posterior thigh muscle injuriesin elite track and field athletes. Am J Sports Med2010;38:1813-1819
[58]. Orchard J, Best TM. The management of muscle strain injuries: an early returnversus the risk of recurrence. Clin J Sport Med2002;12:3-5
[59]. Alfredson H, Lorentzon R. Chronic Achilles tendinosis:recommendations fortreatment and prevention.Sports Med2000;29:135-146
[60]. Armfield DR, Kim DH, Towers JD, Bradley JP, Robertson DD. Sports-relatedmuscle injury in the lower extremity. Clin Sports Med2006;25:803-842
[61]. Liu Y, Kalen A, Risto O, Wahlstrom O. Fibroblast proliferation due to exposureto a platelet concentrate in vitro is pH dependent. Wound Repair Regen2002;10:336-340
[62]. Smith C, Kruger MJ, Smith RM, Myburgh KH.The inflammatory response toskeletal muscle injury:illuminating complexities. Sports Med2008;38:947-969
[63]. Toumi H, Best TM. The inflammatory response:friend or enemy for muscleinjury? Br J Sports Med2003;37:284-286
[64]. Dohan DM, Choukroun J, Diss A, et al. Plateletrich fibrin (PRF):asecond-generation platelet concentrate. Part III. Leucocyte activation: a new featurefor platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod2006;101:e51-e55
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |